Combined RNA interference and gene replacement therapy targeting MFN2 as proof of principle for the treatment of Charcot–Marie–Tooth type 2A
Authors:
Open Access
- 25 November 2023
- journal article
- research article
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 80 (12) , 1-17
Abstract
Mitofusin-2 (MFN2) is an outer mitochondrial membrane protein essential for mitochondrial networking in most cells. Autosomal dominant mutations in the MFN2 gene cause Charcot–Marie–Tooth type 2A disease (CMT2A), a severe and disabling sensory-motor neuropathy that impacts the entire nervous system. Here, we propose a novel therapeutic strategy tailored to correcting the root genetic defect of CMT2A. Though mutant and wild-type MFN2 mRNA are inhibited by RNA interference (RNAi), the wild-type protein is restored by overexpressing cDNA encoding functional MFN2 modified to be resistant to RNAi. We tested this strategy in CMT2A patient-specific human induced pluripotent stem cell (iPSC)-differentiated motor neurons (MNs), demonstrating the correct silencing of endogenous MFN2 and replacement with an exogenous copy of the functional wild-type gene. This approach significantly rescues the CMT2A MN phenotype in vitro, stabilizing the altered axonal mitochondrial distribution and correcting abnormal mitophagic processes. The MFN2 molecular correction was also properly confirmed in vivo in the MitoCharc1 CMT2A transgenic mouse model after cerebrospinal fluid (CSF) delivery of the constructs into newborn mice using adeno-associated virus 9 (AAV9). Altogether, our data support the feasibility of a combined RNAi and gene therapy strategy for treating the broad spectrum of human diseases associated with MFN2 mutations.Keywords
All Related Versions
Funding Information
- Ministero della Salute (GR- 2018-12365358)
- Fondazione Telethon (GGP19002)
- Nomis
- Università degli Studi di Milano
This publication has 71 references indexed in Scilit:
- Disease-Causing Allele-Specific Silencing by RNA InterferencePharmaceuticals, 2013
- Potent and Selective Antisense Oligonucleotides Targeting Single-Nucleotide Polymorphisms in the Huntington Disease Gene / Allele-Specific Silencing of Mutant HuntingtinMolecular Therapy, 2011
- MFN2 mutations cause severe phenotypes in most patients with CMT2ANeurology, 2011
- Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer's disease: implications for neuronal damageHuman Molecular Genetics, 2011
- Silencing ataxin-3 mitigates degeneration in a rat model of Machado–Joseph disease: no role for wild-type ataxin-3?Human Molecular Genetics, 2010
- Diagnosis, natural history, and management of Charcot–Marie–Tooth diseaseThe Lancet Neurology, 2009
- Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytesNature Biotechnology, 2008
- Mitochondrial fusion and function in Charcot–Marie–Tooth type 2A patient fibroblasts with mitofusin 2 mutationsExperimental Neurology, 2008
- Complementation between mouse Mfn1 and Mfn2 protects mitochondrial fusion defects caused by CMT2A disease mutationsJournal of Cell Biology, 2007
- A GFP-based reporter system to monitor nonsense-mediated mRNA decayNucleic Acids Research, 2005